Dr. med. Matthias Egger

06/1996 – 10/1999
Physician in Training and Assistant Physician at St. Josefsklinik, Offenburg, under the medical direction of Prof. Dr. J. Nolte, specializing in Gastroenterology

11/1999 – 07/2000
Assistant Physician at Rosman-Krankenhaus, Breisach, under the medical direction of Dr. B. Walter, specializing in Hematology/Oncology. Founded an emergency physician group in Breisach / Freiburg

08/2000
Joined Department I of the Medical University Clinic, Freiburg, under the medical direction of Prof. Dr. R. Mertelsmann

08/2000 – 09/2001
Medical Emergency Department, Principal Investigator for oncological sonography

10/ 2001– 09/2002
Inpatient wards: Leukemia, Lymphoma, solid tumors

10/2002 – 04/2007
BMT Unit with Outpatient Clinic, allogeneic blood stem cell transplantation. Clinical training of assistant physicians. Supervision of clinical (approval) studies, Principal Investigator Course / ICH-GCP

01/2004
Specialist in Internal Medicine

01/2005
Additional qualification in Emergency Medicine

02/2007
Recognition of subspecialty in Hematology and Internal Oncology

09/2009
ESMO – Examination / 2015 Renewal of ESMO certificate / MORA

2015
Started part-time Master's program MHBA, Prof. Schöffski, Nuremberg

2017
Curriculum for Specialist in Oncological Centers DKG

04/2007
Senior Physician at the Medical Clinic, Gastroenterology, Ortenau-Klinikum, Lahr, Academic Teaching Hospital of the University of Freiburg i.Br. Establishment of the Hematology/Oncology section and the MVZ specialist practice. Implementation of clinical phase II-IV studies

03/2009
Medical Director of the Hematology/Oncology section and MVZ. 02/2010 Authorization for further training in Hematology and Oncology

07/2010
First certification of the Ortenau Oncology Center by the German Cancer Society (DKG), including the Pancreas Center. Coordinator of the Oncology Center at the Lahr location.

01/2014
Deputy Medical Director of the Ortenau Oncology Center

2016
ESMO Designated Centre of Integrated Oncology and Palliative Care

09/2018
ZeTuP Rapperswil

• DGHO German Society for Hematology and Oncology
• DKG German Cancer Society
• AIO Working Group for Internal Oncology
• DPG German Society for Palliative Medicine
• BDI Association of German Internists
• EHA European Hematology Association
• ESMO European Society for Medical Oncology
• ASCO American Society of Clinical Oncology
• IASLC International Association for the Study of Lung Cancer

1. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor
hematopoetic cell transplantation: the feasibility of deescalation. Bertz H, Spyridonidis A, Wäsch R, Grüllich C, Egger M, Finke J.
Biol Blood Marrow Transplant. 2009 Dec;15(12):1563-70. Epub 2009 Oct 1.

2. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host
disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA,Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Finke J; for the ATG-Fresenius Trial Group. Blood. 2011 Jun 9;117(23):6375-6382. Epub 2011 Apr 5.

3. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Lancet Oncol. 2009 Sep;10(9):855-64. Epub 2009 Aug 18.

4. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab.
Schnitzler M, Hasskarl J, Egger M, Bertz H, Finke J. Biol Blood Marrow Transplant. 2009 Aug;15(8):910-8. Erratum in: Biol Blood Marrow Transplant.
2010 Jan;16(1):128.

5. Human metapneumovirus infection in a hematopoietic stem cell transplant recipient with relapsed multiple myeloma and rapidly progressing lung cancer. Huck B, Egger M, Bertz H, Peyerl-Hoffman G, Kern WV, Neumann-Haefelin D, Falcone V. J Clin Microbiol. 2006 Jun; 44(6):2300-3.

6. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Lancet Oncol. 2016 Oct 21. pii: S1470-2045(16)30531-9. doi: 10.1016/S1470-2045(16)30531-9.

7. Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on Newly Diagnosed Elderly Non-Fit AML Patients Michael Lübbert, Olga Grishina, Claudia Schmoor, Richard F. Schlenk, Edgar Jost, Jürgen Krauter, Michael Heuser, Felicitas Thol, Marcus M. Schittenhelm, Helmut R. Salih, Andrea Kuendgen, Ulrich Germing, Katharina Götze, Hans-Walter Lindemann, Carsten Müller-Tidow, Gerhard Heil, Gesine Bug, Carsten Schwänen, Aristoteles Giagounidis, Sebastian Scholl, Andreas Neubauer, Wolfram Brugger, Maike de Wit, Sebastian Schroll, Stephan Kremers, Elisabeth Lange, Johannes Kullmer, Dirk Behringer, Matthias Egger, Irmgard Dresel, Tobias Dechow, Dietger Niederwieser, Maxi Wass, Annette M. May, Ralph Wäsch, Konstanze Döhner, Arnold Ganser, Björn Hackanson, and Hartmut Döhner Blood 2016 128:589; 3 Publikationen II Matthias Egger

8. RadPac A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, Thorsten Oliver Goetze, Susanna Hegewisch- Becker, Jörg Seraphin, Peter C. Thuss-Patience, Hans-Georg Kopp, Tobias Nicolaas Dechow, Arndt Vogel, Kim Barbara Luley, Daniel Pink, Michael Stahl, Frank Kullmann, Holger Frithjof Hebart, Jens T. Siveke, Matthias Egger, Nils Homann, Stephan Probst, Salah-Eddin Al-Batran; J Clin Oncol 35, 2017 (suppl; abstr 4027)

9. A multicentre, phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach (CABAGAST) Harald Schmalenberg, Claudia Pauligk, Thomas Zander, Alexander Reichart, Udo Lindig, Mathias Kleiss, Lothar Müller, Claus Bolling, Thomas Seufferlein, Peter Reichardt, Frank Kullmann, Henning Eschenburg, Alexander Schmittel, Matthias Egger, Andreas Block, Salah-Eddin Al-Batran, Thorsten Oliver Goetze; J Clin Oncol 35, 2017 (suppl; abstr 4054)

10. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD. JAMA Oncol. 2017 Sep 1;3(9):1237-1244.

11. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach. Harald Schmalenberg, Salah-Eddin Al-Batran, Claudia Pauligk, Thomas Zander, Alexander Reichart, Udo Lindig, Mathias Kleiß, Lothar Müller, Claus Bolling, Thomas Seufferlein, Peter Reichardt, Frank Kullmann, Henning Eschenburg, Alexander Schmittel, Matthias Egger, Andreas Block, Thorsten Oliver Goetze Journal of Cancer Research and Clinical Oncology 2017 Dec online

12. Co-authorship:

– ASCO
2013 Interim safety analysis of a phase III trial with 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/ oesophago-gastric junction (OGJ) cancer: The AIO-STO-0210 FLOT4 study

– ASCO 2015
Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO.

– further information: ESMO 2015, DGHO 2015, ASCO GI 2017